To include your compound in the COVID-19 Resource Center, submit it here.

Zynerba reports additional data for epilepsy candidate ZYN002

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported data from 171 patients with confirmed refractory epilepsy with focal seizures with or without secondary generalization who completed the Phase II STAR 1 trial and were enrolled in the

Read the full 345 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers